Ticker brief
RYTM
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
5
authors 14d
5
crowd 14d
+0.0σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-09 → 2026-10-14 · now +0.35 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -1.06 | 1 | +0.40 |
| @Quantumup1 | C | +0.10 | 1 | +0.40 |
| @AlertsAndNews | C | -3.92 | 1 | +0.35 |
| @PrismMarketView | C | · | 1 | +0.40 |
| @PrismDM | A | -2.76 | 1 | +0.30 |
Recent signals5of 5 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-14 | @PrismDM | +0.30 | Rhythm launched IMCIVREE in Japan following regulatory approval. | · | tweet ↗ |
| 2026-10-14 | @PrismMarketView | +0.40 | IMCIVREE commercially launched in Japan following regulatory approval. | · | tweet ↗ |
| 2026-10-13 | @AlertsAndNews | +0.35 | Rhythm Pharmaceuticals announced the commercial launch of IMCIVREE in Japan. | · | tweet ↗ |
| 2026-10-12 | @Quantumup1 | +0.40 | H.C. Wainwright raised Rhythm's target to $130 from $105 and reiterated Buy. | · | tweet ↗ |
| 2026-10-09 | @semodough | +0.40 | BofA reiterates Buy and raises RYTM's price target to $150, citing a $3.1B peak-sales estimate. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.